1. Home
  2. APOG vs XERS Comparison

APOG vs XERS Comparison

Compare APOG & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APOG
  • XERS
  • Stock Information
  • Founded
  • APOG 1949
  • XERS 2005
  • Country
  • APOG United States
  • XERS United States
  • Employees
  • APOG N/A
  • XERS N/A
  • Industry
  • APOG Auto Parts:O.E.M.
  • XERS Biotechnology: Pharmaceutical Preparations
  • Sector
  • APOG Consumer Discretionary
  • XERS Health Care
  • Exchange
  • APOG Nasdaq
  • XERS Nasdaq
  • Market Cap
  • APOG 919.3M
  • XERS 752.7M
  • IPO Year
  • APOG N/A
  • XERS 2018
  • Fundamental
  • Price
  • APOG $45.19
  • XERS $7.75
  • Analyst Decision
  • APOG Hold
  • XERS Strong Buy
  • Analyst Count
  • APOG 1
  • XERS 7
  • Target Price
  • APOG $45.00
  • XERS $6.79
  • AVG Volume (30 Days)
  • APOG 139.0K
  • XERS 3.4M
  • Earning Date
  • APOG 10-03-2025
  • XERS 08-07-2025
  • Dividend Yield
  • APOG 2.45%
  • XERS N/A
  • EPS Growth
  • APOG N/A
  • XERS N/A
  • EPS
  • APOG 2.36
  • XERS N/A
  • Revenue
  • APOG $1,376,100,000.00
  • XERS $246,025,000.00
  • Revenue This Year
  • APOG $6.91
  • XERS $35.31
  • Revenue Next Year
  • APOG $0.41
  • XERS $19.65
  • P/E Ratio
  • APOG $19.13
  • XERS N/A
  • Revenue Growth
  • APOG N/A
  • XERS 35.62
  • 52 Week Low
  • APOG $37.53
  • XERS $2.48
  • 52 Week High
  • APOG $87.93
  • XERS $7.79
  • Technical
  • Relative Strength Index (RSI)
  • APOG 62.29
  • XERS 80.09
  • Support Level
  • APOG $41.46
  • XERS $7.27
  • Resistance Level
  • APOG $44.11
  • XERS $7.79
  • Average True Range (ATR)
  • APOG 1.21
  • XERS 0.41
  • MACD
  • APOG 0.16
  • XERS 0.08
  • Stochastic Oscillator
  • APOG 93.55
  • XERS 98.43

About APOG Apogee Enterprises Inc.

Apogee Enterprises Inc is a provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. The company's operating segment consists of the Architectural Metals Segment, Architectural Services Segment, Architectural Glass Segment, and Performance Surfaces Segment. The company generates the majority of its revenue from the Architectural Metals Segment, which designs, engineers, fabricates, and finishes aluminum window, curtainwall, storefront, and entrance systems used principally in non-residential construction. The company generates revenue geographically from the United States, Canada, and Brazil, with the majority coming from the United States.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Share on Social Networks: